• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Jupiter Neurosciences Inc.

    4/1/26 4:38:05 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email
    NT 10-K 1 formnt-10k.htm NT 10-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one):  

    ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q

    ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

       
        For Period Ended: December 31, 2025
       
        ☐Transition Report on Form 10-K
        ☐ Transition Report on Form 20-F
        ☐ Transition Report on Form 11-K
        ☐ Transition Report on Form 10-Q
        ☐ Transition Report on Form N-SAR
       
        For the Transition Period Ended:

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Jupiter Neurosciences, Inc.

    Full Name of Registrant

     

    1001 North US HWY 1

    Suite 504

    Address of Principal Executive Office (Street and Number)

     

    Jupiter, Florida 33477

    City, State and Zip Code

     

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

     

    Jupiter Neurosciences, Inc. (the “Company”) is unable to file the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) in a timely manner without unreasonable effort or expense. Although the Company had substantially completed the preparation of the Form 10-K, it was unable to finalize and submit the filing prior to the prescribed deadline of March 31, 2026 due to missing the 5:30 p.m. Eastern Time filing cutoff. The Company is continuing to finalize the Form 10-K and expects to file the Form 10-K by April 1, 2026.

     

    Part IV - Other Information

     

    1. Name and telephone number of person to contact in regard to this notification

     

      Christer Rosén   (561)   406-6154
      (Name)   (Area Code)   (Telephone Number)

     

    2. Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    Yes ☒ No ☐

     

    3. Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    Yes ☐ No ☒

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    Jupiter Neurosciences, Inc.

    (Name of Registrant as Specified in Charter)

     

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 1, 2026 By: /s/ Christer Rosén
        Christer Rosén
      Title: Chief Executive Officer

     

     

    Get the next $JUNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    SEC Filings

    View All

    SEC Form 10-K filed by Jupiter Neurosciences Inc.

    10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    4/1/26 4:45:31 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Jupiter Neurosciences Inc.

    NT 10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    4/1/26 4:38:05 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure

    8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    2/27/26 4:30:55 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Jupiter Neurosciences to Present at Emerging Growth Conference on April 2

    JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to announce that it has been invited to present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. Jupiter invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at: https://goto.webcasts.com/starthere.jsp?ei=1748971&tp_key=add80b0ab6&sti=juns If attendees are not able to join the event live on the

    3/31/26 12:00:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pres + Chief Business Officer Silva Alison D.

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/7/25 9:28:07 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and Secretary Elmasri Saleem converted options into 66,293 shares (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/7/25 9:28:09 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 8:56:52 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 8:56:52 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 2:53:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/1/25 7:55:51 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care